96.Issue 10 october 25 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 12, Issue : 10, October – 2025

Title:

FORMULATION AND EVALUATION OF AZITHROMYCIN SUSTAIN RELEASE TABLETS

Authors :

Alige Sudharani*, T. Vijaya kumari, Dr. D. Venkata ramana.

Abstract :

Today’s goal was to transfer two (200 mg) of a two-way direct compression matrix into two durable free matrix bearings, using polymers like chewing gum, pectin and. Two studies on the two drugs were carried out two combinations. Two studies were conducted on both tablets, drug release, two kinetic researches. The FTIR confirmed that two of them had become two without the interaction between polymers and drugs. The pony houses were placed at the edges. Both should be better used to manage or maintain infections that have been demonstrated or suspected of being cut by microorganisms if they choose to develop antimicrobial resistance and develop the efficacy of two seeds of two forms optimized for a duration of 12 hours. The kinetic treatment of the selected components (F8) found that the release of the drug follows the release kinetics. The results of the present seem to indicate the suitability of polymers for the practice of an extended-release device, in particular based on the matrix.
Keywords: Azithromycin, Acacia, Pectin and Karaya gum and Sustained release tablets.

Cite This Article:

Please cite this article in press Alige Sudharani et al., Formulation And Evaluation Of Azithromycin Sustain Release Tablets , Indo Am. J. P. Sci, 2025; 12(10).

REFERENCES:

1. Altaf AS, Friend DR, MASRx and COSRx. Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, Modified Release Drug Delivery Technology, Marcell Dekker Inc., New York, 2003; 1: 102-117.
2. Reddy KR., Mutalik S, Reddy S. AAPS Pharm. Sci. Tech.2003; 4: 19. 121-125.
3. Mohammed AD et al. Release of propranolol hydrochloride from matrix tablets containing sodium carboxymethylcellulose and Hydroxypropyl methyl cellulose. Pharm Dev Tech.1999; 4: 313-324.
4. Salsa T, Veiga F. Drug Develop. Ind Pharm. 1997; 23: 931.
5. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, inBanker GS, Rhodes CT (Eds.) Modern Pharmaceutics, 3rd Ed, Revised andExpanded, Drugs and the Pharmaceutical Sciences., Marcell Dekker, Inc. NewYork. 1995; 72: 575-609.
6. Jantzen GM, Robinson JR. Sustained and Controlled- Release Drug Delivery systems Modern Pharmaceutics, 4thed; 2003; 121: 501-502.
7. Lee BJ, Ryu SG, Cui JH, Drug Dev. Ind.Pharm.1999; 25: 493-501.
8. Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Ed. Modern Pharmaceutics, 3rdEd Marcel Dekker Inc. New York. 1996; 72: 575.
9. Vidyadhara S, Rao PR, Prasad JA. Indian J Pharm Sci. 2004; 66: 188-192.
10. Bogner RH. Bioavailability and bioequivalence of extended-release oral dosage forms. US Pharmacist. 1997; 22: 3–12.
11. Rogers JD, Kwan KC. Pharmacokinetic requirements for controlled-release dosage forms. In: John Urquhart, ed. Controlled-release Pharmaceuticals. Academy of Pharmaceutical Sciences. American Pharmaceutical Association. 1979: 95–119.
12. Madan PL. Sustained-release drug delivery systems, part II: Preformulation considerations. Pharm Manu fact. 1985; 2: 41–45.
13. Wani MS, Controlled Release System-A Review, 2008; 6 1: 56-62.
14. Banker GS, Anderson NR. The Theory and Practice of Industrial Pharmacy: Tablet,Lachman, (3rded) Varghese Publishing House, Bombay. 1990; 3: 293-303.
15. Lee VHL, Controlled Drug Delivery Fundamentals and Applications: Influence of drug properties on design, Marcel Dekker, INC, and New York. 1987; 2: 16-29.
16. Manish R, Jayesh P, Siahboomi AR. Hydrophilic Matrices for Oral Extended Release: Influence of Fillers on Drug Release from HPMC Matrices. Pharma Times. 2010; 42(04): 67-73.
17. Kumar KP et al. Innovations in Sustained Release Drug Delivery System and Its Market Opportunities. J Chem Pharm Res. 2010; 2 1: 349-360.
18. Brahmankar DM, Sunil B. Jaishwal. “Controlled release medication” chapter 15th in “Bio pharmaceutics and Pharmacokinetics – A Treatise, 1st ed, 2010; 1: 347- 353.
19. Stanley S. Davis, Formulation strategies for abs windows. Drug Discovery Today, 2005; 10: 249-257.
20. Modi SA et al. Sustained Release Drug Delivery System:A Review.Int J Pharma. Res Dev. 2011; 2 (12): 147-160.
21. Lieberman HA, Lachman L, Schwartz JB., Pharmaceutical Dosage Forms: Tablets, 2011; 3 (2): 199-287.
22. Aulton ME. Pharmaceutics: The Science of Dosage Form Design. 2005; 2: 296-298.
23. Wise DL. Handbook of Pharmaceutical Controlled Release Technology. Inc. 2005; 2: 5-24.
24. Jantzen GM, Robinson JR. Sustained and Controlled- Release Drug Delivery systems Modern Pharmaceutics, 4thed; 2011; 121: 501-502.
25. Bhargava.A et al. Oral sustained release dosage form: an opportunity to prolong the release of drug.IntJ ARPB. 2013; 3: 7-14.
26. Tapaswi Rani Dash, PankajVerma. Matrix Tablets: An Approach towards Oral Extended Release Drug Delivery. Int J Pharm Res & Rev. 2013; 2 2:12-24.
27. Crist B, Spisak D. Evaluation Of Induced Variance Of Physical Parameters On The Calibrated USP Dissolution Apparatus 1 And 2. Diss. Tech. 12;28-31:2005.
28. David B Jacoby. Pathophysiology of airway viral infections. Pulmonary Pharmacology & Therapeutics.17;333-336:2004.
29. Davies PN, Worthington HEC, Podczeck F, Newton JM. The Determination Of The Mechanical Strength Of Tablets Of Different Shapes. Eur J Pharm Biopharm. 67(1);268-276:2007.
30. Desai S, Bolton S. A Floating Controlled –Release Drug Delivery System:In-Vitro & In-Vivo Evaluation. Pharm. Res. 10(9);1321-1325:1993.
31. Md. Mofizur Rahman, Formulation and evaluation of Ranolazine sustained release matrix tablets using Eudragit and HPMC International journal of pharma research and development, 2011, 2 1, 7-12
32. P. Mahajan, Valsartan release from sustained release matrix tablet and effect of cellulose derivatives, international journal of pharmacy & life sciences-2011; 2: 112-115.
33. Chandra sekhar. Y1 Formulation and Invitro Evaluation of Didanosine Sustained Release Matrix Tablets using Natural Gums International Journal of Research in Pharmaceutical and Biomedical Sciences, 2011; 2: 54-58.
34. N.Aruna,Formulation And Evaluation Of Sustained Release Matrix Tablets Containing Metformin Hcl And Syzygium cumin International Journal of Pharmaceutical & Biological Archives 2011; 2: 112-115.
35. Sameer shafi,formulation and evaluation of sintered matrix tablets of diltiazem hydrochloride ,international journal of pharmaceuticeuts 2011; 3: 67-73.
36. Kamlesh J.Formulation of Sustained Release Metformin Hydrochloride Matrix Tablets: Influence of Hydrophilic Polymers on the Release Rate And In Vitro Evaluation, International Journal of Research in Controlled Release, 2011; 9-16: 43-49.
37. G.N.K.GaneshPreparation and Evaluation of Sustained Release Matrix Tablet of Diclofenac Sodium using Natural Polymer journal of pharmaceutical research.2010; 2 6: 103-107.
38. Anroop B. controlled release matrix uncoated tablets of enalapril maleate using hpmc alone journal of Basic and Clinical Pharmacy, 2010; 2 (1): 106-112.
39. RajuMandaFormulation and In-Vitro Evaluation of sustained release Matrix Tabelts of Aceclofenac by using different natural polymars. 2010; 1: 87-89.
40. Margret chandira, formulation and evaluation of sustained release matrix tablets of Zidovudine, International Journal of Current Pharmaceutical Research, 2009; 1: 76-82.
41. N.G.Raghavendra rao, formulation and evaluation of zero order release glipizide bilayer matrix tablets using natural and synthetic polymers International Journal of Current Pharmaceutical Research 2009; 1: 87-92.
42. Laksmana prabu Formulation and evaluation of oral sustained release of Diltiazem Hydrochloride using rosin as matrix forming material ARS Pharmaceutica, 2009; 50: 100-104.
43. Sourabh Jain, Preparation and Evaluation of Sustained Release Matrix Tablet of Furosemide using Natural Polymers,Research Journal of Pharmaceutical, Biological and Chemical Sciences ,2008; 279: 34-39.
44. www.Drug bank.com.
45. Handbook of Pharmaceutical Excipients, sixth edition, edited by Raymond C Rowe, Paul J Sheskey and Marian E Quinn, 326-329.
46. Handbook of Pharmaceutical Excipients, sixth edition, edited by Raymond C Rowe, Paul J Sheskey and Marian E Quinn, 298-300.
47. Handbook of Pharmaceutical Excipients, sixth edition, edited by Raymond C Rowe, Paul J Sheskey and Marian E Quinn, 782-785.
48. Handbook of Pharmaceutical Excipients, sixth edition, edited by Raymond C Rowe, Paul J Sheskey and Marian E Quinn, 527.
49. Handbook of Pharmaceutical Excipients, sixth edition, edited by Raymond C Rowe, Paul J Sheskey and Marian E Quinn, 133-136.
50. Handbook of Pharmaceutical Excipients, sixth edition, edited by Raymond C Rowe, Paul J Sheskey and Marian E Quinn, 400-406
51. Handbook of Pharmaceutical Excipients, sixth edition, edited by Raymond C Rowe, Paul J Sheskey and Marian E Quinn, 761-768.
52. Design and in vitro evaluation of sustained release tablets of ranolazine.M. RangaPriya, R. Natarajan and N. N. Rajendran Department of Pharmaceutics & Research, SwamyVivekanandha College of Pharmacy, 2012; 2: 112-116.
53. Development of sustain release matrix tablet of ranolazine based on Methoeel k4m GR: invitrodrug release and kinetic approach Md. Asaduzzaman, Md. RezowanurRahman, Md. SaifurRahman Khan and S.M. Ashraful Islam 2011; 2 1: 46-49.
54. Md. MofizurRahman, SayeedHasan, Md. AshiqulAlam, Sumon Roy, Mithilesh Kumar Jha, Md. Qamrul Ahsan4, Md. HabiburRahman. Formulation and evaluation of Ranolazine sustained release matrix tablets using Eudragit and HPMC. 2011; 2: 106-110.
55. Journal of chemical and pharmaceutical research. Formulation and evaluation of ranolazine extended released tablets. B.Mayuri, Madhu.E.Nicholas, SY Manjunath. SubalDebnath. 2010; 2: 121-127.
56. The theory and practice of Industrial Pharmacy, Leon Lachman, Herbert A.Liberman, special Indian edition 2009; 1: 293-345.
57. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. New Engl J Med.1998, 339: 1044-1053.
58. Gibb WR. Neuropathology of Parkinson’s disease and related syndromes. NeurolClin.1992; 10: 361-376.
59. Fearnley J, Lees A. Pathology of Parkinson’s disease. In, Neurodegenerative Diseases.(Calne, D.B., ed.) Saunders, Philadelphia.1994; 545-554.
60. Kumar S, Gupta V, Malodia K. Oral Extended Release Drug Delivery System: A Promising Approach. Asian J Pharm Tech. 2012; 2 2: 38-43.